UBS Group initiated coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) in a research note published on Friday morning, Marketbeat reports. The firm issued a buy rating and a $21.00 price objective on the stock.
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 2.0 %
TLX traded down $0.30 during trading on Friday, hitting $14.85. 40,166 shares of the company’s stock traded hands. Telix Pharmaceuticals Limited American Depositary Shares has a 12-month low of $14.81 and a 12-month high of $19.99.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Technology Stocks Explained: Here’s What to Know About Tech
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- 5 discounted opportunities for dividend growth investors
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What is a Death Cross in Stocks?
- Time to Load Up on Home Builders?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
